TABLE OF CONTENTS
1. EXECUTIVE SUMMARY
1.1. Market Overview
1.2. Key Findings
1.3. Market Segmentation
1.4. Competitive Landscape
1.5. Challenges and Opportunities
1.6. Future Outlook
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the study
2.2.1. Research Objective
2.2.2. Assumption
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Model
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Value chain Analysis
5.2. Porter's Five Forces Analysis
5.2.1. Bargaining Power of Suppliers
5.2.2. Bargaining Power of Buyers
5.2.3. Threat of New Entrants
5.2.4. Threat of Substitutes
5.2.5. Intensity of Rivalry
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Regional Impact
5.3.3. Opportunity and Threat Analysis
6. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TEST TYPE (USD BILLION)
6.1. Biomarker Testing
6.2. Genetic Testing
6.3. Proteomic Testing
6.4. Pharmacogenetic Testing
7. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY (USD BILLION)
7.1. Polymerase Chain Reaction
7.2. Next Generation Sequencing
7.3. In Situ Hybridization
8. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION (USD BILLION)
8.1. Breast Cancer
8.2. Lung Cancer
8.3. Colorectal Cancer
8.4. Other Cancers
9. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER (USD BILLION)
9.1. Hospitals
9.2. Diagnostic Laboratories
9.3. Research Institutes
10. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGIONAL (USD BILLION)
10.1. North America
10.1.1. US
10.1.2. Canada
10.2. Europe
10.2.1. Germany
10.2.2. UK
10.2.3. France
10.2.4. Russia
10.2.5. Italy
10.2.6. Spain
10.2.7. Rest of Europe
10.3. APAC
10.3.1. China
10.3.2. India
10.3.3. Japan
10.3.4. South Korea
10.3.5. Malaysia
10.3.6. Thailand
10.3.7. Indonesia
10.3.8. Rest of APAC
10.4. South America
10.4.1. Brazil
10.4.2. Mexico
10.4.3. Argentina
10.4.4. Rest of South America
10.5. MEA
10.5.1. GCC Countries
10.5.2. South Africa
10.5.3. Rest of MEA
11. COMPETITIVE LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market share Analysis
11.4. Major Growth Strategy in the Companion Diagnostics for Oncology Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Companion Diagnostics for Oncology Market
11.7. Key developments and growth strategies
11.7.1. New Product Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial Matrix
11.8.1. Sales and Operating Income
11.8.2. Major Players R&D Expenditure. 2023
12. COMPANY PROFILES
12.1. Qiagen
12.1.1. Financial Overview
12.1.2. Products Offered
12.1.3. Key Developments
12.1.4. SWOT Analysis
12.1.5. Key Strategies
12.2. Agilent Technologies
12.2.1. Financial Overview
12.2.2. Products Offered
12.2.3. Key Developments
12.2.4. SWOT Analysis
12.2.5. Key Strategies
12.3. Eli Lilly and Company
12.3.1. Financial Overview
12.3.2. Products Offered
12.3.3. Key Developments
12.3.4. SWOT Analysis
12.3.5. Key Strategies
12.4. Biocartis
12.4.1. Financial Overview
12.4.2. Products Offered
12.4.3. Key Developments
12.4.4. SWOT Analysis
12.4.5. Key Strategies
12.5. HoffmannLa Roche
12.5.1. Financial Overview
12.5.2. Products Offered
12.5.3. Key Developments
12.5.4. SWOT Analysis
12.5.5. Key Strategies
12.6. Illumina
12.6.1. Financial Overview
12.6.2. Products Offered
12.6.3. Key Developments
12.6.4. SWOT Analysis
12.6.5. Key Strategies
12.7. Thermo Fisher Scientific
12.7.1. Financial Overview
12.7.2. Products Offered
12.7.3. Key Developments
12.7.4. SWOT Analysis
12.7.5. Key Strategies
12.8. Genomic Health
12.8.1. Financial Overview
12.8.2. Products Offered
12.8.3. Key Developments
12.8.4. SWOT Analysis
12.8.5. Key Strategies
12.9. Abbott Laboratories
12.9.1. Financial Overview
12.9.2. Products Offered
12.9.3. Key Developments
12.9.4. SWOT Analysis
12.9.5. Key Strategies
12.10. Amgen
12.10.1. Financial Overview
12.10.2. Products Offered
12.10.3. Key Developments
12.10.4. SWOT Analysis
12.10.5. Key Strategies
12.11. Myriad Genetics
12.11.1. Financial Overview
12.11.2. Products Offered
12.11.3. Key Developments
12.11.4. SWOT Analysis
12.11.5. Key Strategies
12.12. Merck KGaA
12.12.1. Financial Overview
12.12.2. Products Offered
12.12.3. Key Developments
12.12.4. SWOT Analysis
12.12.5. Key Strategies
12.13. Celerion
12.13.1. Financial Overview
12.13.2. Products Offered
12.13.3. Key Developments
12.13.4. SWOT Analysis
12.13.5. Key Strategies
12.14. Roche
12.14.1. Financial Overview
12.14.2. Products Offered
12.14.3. Key Developments
12.14.4. SWOT Analysis
12.14.5. Key Strategies
12.15. AstraZeneca
12.15.1. Financial Overview
12.15.2. Products Offered
12.15.3. Key Developments
12.15.4. SWOT Analysis
12.15.5. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports
LIST OF TABLES
TABLE 1. LIST OF ASSUMPTIONS
TABLE 2. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 3. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 4. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 5. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 6. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 7. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 8. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 9. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 10. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 11. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 12. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 13. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 14. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 15. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 16. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 17. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 18. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 19. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 20. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 21. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 22. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 23. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 24. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 25. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 26. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 27. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 28. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 29. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 30. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 31. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 32. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 33. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 34. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 35. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 36. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 37. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 38. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 39. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 40. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 41. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 42. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 43. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 44. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 45. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 46. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 47. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 48. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 49. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 50. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 51. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 52. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 53. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 54. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 55. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 56. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 57. APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 58. APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 59. APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 60. APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 61. APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 62. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 63. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 64. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 65. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 66. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 67. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 68. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 69. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 70. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 71. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 72. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 73. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 74. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 75. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 76. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 77. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 78. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 79. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 80. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 81. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 82. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 83. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 84. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 85. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 86. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 87. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 88. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 89. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 90. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 91. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 92. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 93. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 94. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 95. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 96. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 97. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 98. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 99. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 100. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 101. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 102. SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 103. SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 104. SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 105. SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 106. SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 107. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 108. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 109. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 110. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 111. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 112. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 113. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 114. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 115. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 116. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 117. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 118. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 119. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 120. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 121. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 122. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 123. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 124. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 125. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 126. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 127. MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 128. MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 129. MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 130. MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 131. MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 132. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 133. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 134. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 135. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 136. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 137. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 138. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 139. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 140. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 141. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 142. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TEST TYPE, 2019-2032 (USD BILLIONS)
TABLE 143. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY TECHNOLOGY, 2019-2032 (USD BILLIONS)
TABLE 144. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY INDICATION, 2019-2032 (USD BILLIONS)
TABLE 145. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY END USER, 2019-2032 (USD BILLIONS)
TABLE 146. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET SIZE ESTIMATES & FORECAST, BY REGIONAL, 2019-2032 (USD BILLIONS)
TABLE 147. PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
TABLE 148. ACQUISITION/PARTNERSHIP
LIST OF FIGURES
FIGURE 1. MARKET SYNOPSIS
FIGURE 2. NORTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS
FIGURE 3. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 4. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 5. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 6. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 7. US COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 8. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 9. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 10. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 11. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 12. CANADA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 13. EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS
FIGURE 14. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 15. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 16. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 17. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 18. GERMANY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 19. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 20. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 21. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 22. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 23. UK COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 24. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 25. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 26. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 27. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 28. FRANCE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 29. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 30. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 31. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 32. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 33. RUSSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 34. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 35. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 36. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 37. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 38. ITALY COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 39. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 40. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 41. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 42. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 43. SPAIN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 44. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 45. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 46. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 47. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 48. REST OF EUROPE COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 49. APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS
FIGURE 50. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 51. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 52. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 53. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 54. CHINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 55. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 56. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 57. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 58. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 59. INDIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 60. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 61. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 62. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 63. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 64. JAPAN COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 65. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 66. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 67. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 68. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 69. SOUTH KOREA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 70. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 71. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 72. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 73. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 74. MALAYSIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 75. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 76. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 77. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 78. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 79. THAILAND COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 80. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 81. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 82. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 83. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 84. INDONESIA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 85. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 86. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 87. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 88. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 89. REST OF APAC COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 90. SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS
FIGURE 91. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 92. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 93. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 94. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 95. BRAZIL COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 96. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 97. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 98. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 99. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 100. MEXICO COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 101. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 102. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 103. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 104. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 105. ARGENTINA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 106. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 107. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 108. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 109. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 110. REST OF SOUTH AMERICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 111. MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS
FIGURE 112. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 113. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 114. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 115. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 116. GCC COUNTRIES COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 117. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 118. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 119. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 120. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 121. SOUTH AFRICA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 122. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TEST TYPE
FIGURE 123. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY TECHNOLOGY
FIGURE 124. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY INDICATION
FIGURE 125. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY END USER
FIGURE 126. REST OF MEA COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET ANALYSIS BY REGIONAL
FIGURE 127. KEY BUYING CRITERIA OF COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET
FIGURE 128. RESEARCH PROCESS OF MRFR
FIGURE 129. DRO ANALYSIS OF COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET
FIGURE 130. DRIVERS IMPACT ANALYSIS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET
FIGURE 131. RESTRAINTS IMPACT ANALYSIS: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET
FIGURE 132. SUPPLY / VALUE CHAIN: COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET
FIGURE 133. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TEST TYPE, 2024 (% SHARE)
FIGURE 134. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TEST TYPE, 2019 TO 2032 (USD Billions)
FIGURE 135. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2024 (% SHARE)
FIGURE 136. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY TECHNOLOGY, 2019 TO 2032 (USD Billions)
FIGURE 137. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2024 (% SHARE)
FIGURE 138. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY INDICATION, 2019 TO 2032 (USD Billions)
FIGURE 139. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2024 (% SHARE)
FIGURE 140. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY END USER, 2019 TO 2032 (USD Billions)
FIGURE 141. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGIONAL, 2024 (% SHARE)
FIGURE 142. COMPANION DIAGNOSTICS FOR ONCOLOGY MARKET, BY REGIONAL, 2019 TO 2032 (USD Billions)
FIGURE 143. BENCHMARKING OF MAJOR COMPETITORS
